(Q53277854)

12 May 2018

title

Expression of p-JAK2 predicts clinical outcome and is a potential molecular target of acute myelogenous leukemia. (English)

1 reference

12 May 2018

1 reference

Takayuki Ikezoe

1

1 reference

12 May 2018

Shinsuke Kojima

2

1 reference

12 May 2018

Mutsuo Furihata

3

1 reference

12 May 2018

Jing Yang

4

1 reference

12 May 2018

Chie Nishioka

5

1 reference

12 May 2018

Asako Takeuchi

6

1 reference

12 May 2018

Mayuka Isaka

7

1 reference

12 May 2018

H Phillip Koeffler

8

1 reference

12 May 2018

Akihito Yokoyama

9

1 reference

12 May 2018

language of work or name

English

0 references

publication date

8 April 2011

1 reference

12 May 2018

International Journal of Cancer

published in

1 reference

12 May 2018

volume

129

1 reference

12 May 2018

issue

10

1 reference

12 May 2018

page(s)

2512-2521

1 reference

12 May 2018

Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell

cites work

1 reference

21 January 2018

The Janus kinases (Jaks)

1 reference

The STATs of cancer--new molecular targets come of age

21 January 2018

1 reference

Hematopoietic cytokine receptor signaling

21 January 2018

1 reference

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

21 January 2018

1 reference

JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis.

21 January 2018

1 reference

Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F.

21 January 2018

1 reference

Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model

21 January 2018

1 reference

JAK mutations in high-risk childhood acute lymphoblastic leukemia

21 January 2018

1 reference

Constitutive activation of STAT transcription factors in acute myelogenous leukemia

21 January 2018

1 reference

The antitumor effects of sunitinib (formerly SU11248) against a variety of human hematologic malignancies: enhancement of growth inhibition via inhibition of mammalian target of rapamycin signaling

21 January 2018

1 reference

Effects of the JAK2 inhibitor, AZ960, on Pim/BAD/BCL-xL survival signaling in the human JAK2 V617F cell line SET-2.

21 January 2018

1 reference

Analysis of Aurora B kinase in non-Hodgkin lymphoma

21 January 2018

1 reference

Ki11502, a novel multitargeted receptor tyrosine kinase inhibitor, induces growth arrest and apoptosis of human leukemia cells in vitro and in vivo

21 January 2018

1 reference

The meaning and use of the area under a receiver operating characteristic (ROC) curve

21 January 2018

1 reference

JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin

21 January 2018

1 reference

Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency

21 January 2018

1 reference

The T cell leukemia LIM protein Lmo2 is necessary for adult mouse hematopoiesis.

21 January 2018

1 reference

Selective activation of STAT5 unveils its role in stem cell self-renewal in normal and leukemic hematopoiesis

21 January 2018

1 reference

Conditional deletion of STAT5 in adult mouse hematopoietic stem cells causes loss of quiescence and permits efficient nonablative stem cell replacement

21 January 2018

1 reference

JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/IJC.25910

1 reference

12 May 2018

1 reference

12 May 2018